Cart (Loading....) | Create Account
Close category search window

Sonophoresis with ultrasound contrast agents in transdermal drug delivery: In vivo experimental study

Sign In

Cookies must be enabled to login.After enabling cookies , please use refresh or reload or ctrl+f5 on the browser for the login options.

Formats Non-Member Member
$31 $13
Learn how you can qualify for the best price for this item!
Become an IEEE Member or Subscribe to
IEEE Xplore for exclusive pricing!
close button

puzzle piece

IEEE membership options for an individual and IEEE Xplore subscriptions for an organization offer the most affordable access to essential journal articles, conference papers, standards, eBooks, and eLearning courses.

Learn more about:

IEEE membership

IEEE Xplore subscriptions

6 Author(s)
Park, D. ; Dept. of Biomed. Eng., Yonsei Univ., Wonju, South Korea ; Ryu, H. ; Namgung, M. ; Choi, K.
more authors

Sonophoresis for transdermal drug delivery(TDD) generally uses relatively low frequency ultrasound (e.g., <;100 kHz). The main mechanism of sonophoresis is related to cavitation of bubbles trapped between ultrasound transducer and skin. Thus, enhancement of cavitation can lead to effective TDD. In this presentation, the efficacy of TDD with ultrasound contrast agent(UCA) was tested by animal experiments. FITC(Fluorescein isothiocyanate) Dextran(the concentration of 1g/80ml, molecular weight of 4k, 20k, 150k) with 0.1% UCA was used as the drug to be delivered through the skin. Two type of UCAs, Sonovue® and Definity®, were used in the experiments at 2.47 MHz and 1.12 MHz, respectively, according to their resonance frequency. Ultrasound is applied on the back of rat whose hair is removed. One spot was always reserved for the control experiment and the other spot was used for three different conditional experiments. The first condition was ultrasound at two different frequencies without UCA, the second condition was 1.12 MHz ultrasound with Definity®, and the third condition was 2.24 MHz ultrasound with Sonovue®, respectively. A pulse of 10 msec with 1% duty cycle was used at the acoustic pressure of 1 MPa for 30 minutes in all the experiments. The efficacy of sonophoresis with 0.1% UCAs was quantitatively analyzed with optical imaging system (IVIS® Spectrum) which was used to count photons emitted from fluorescein at the wavelength of 520nm. Histological analysis of the rat skin exposed to sonophoresis was performed to assess the safety. Application of ultrasound without UCA increases the photon count approximately 20.8% , 13.6%, 17.4% at 1.12 MHz and 6.3%, 22.5%, 22.3% at 2.47 MHz for three different Dextran of 4k , 20k , 150k , respectively. With UCA presence, the increments of photon counts were approximately 53.6%, 47.3%, 47.8% at 1.12 MHz and 48.9%, 50.8%, 44.4% at 2.47 MHz for the same three Dextran, respectively. Acco- - rding to the histological analysis, no damage to the tissue. Sonophoresis for TDD was safely and more effectively conducted with the aid of UCA, even though cavitation is a stochastic event. Optimization of ultrasound parameters such as intensity, duty cycle, concentration of UCA is expected to enhance sonophoresis. We believe sonophoresis with UCA has broad applications for various skin diseases.

Published in:

Ultrasonics Symposium (IUS), 2010 IEEE

Date of Conference:

11-14 Oct. 2010

Need Help?

IEEE Advancing Technology for Humanity About IEEE Xplore | Contact | Help | Terms of Use | Nondiscrimination Policy | Site Map | Privacy & Opting Out of Cookies

A not-for-profit organization, IEEE is the world's largest professional association for the advancement of technology.
© Copyright 2014 IEEE - All rights reserved. Use of this web site signifies your agreement to the terms and conditions.